NDAORALTABLET
Approved
Oct 2013
Lifecycle
Peak
Competitive Pressure
0/100
Clinical Trials
37
Mechanism of Action
Guanylate Cyclase Stimulators
Pharmacologic Class:
Soluble Guanylate Cyclase Stimulator
Clinical Trials (5)
Efficacy and Safety of Riociguat in Incipient Pulmonary Vascular Disease as an Indicator for Early PAH
Started Oct 2022
35 enrolled
Pulmonary Vascular DisorderPrimary Pulmonary HypertensionSystemic Sclerosis+1 more
Effects of Riociguat on RIght VEntricular Size and Function in PAH and CTEPH
Started Apr 2022
30 enrolled
Primary Pulmonary Arterial HypertensionChronic Thromboembolic Pulmonary Hypertension
A Study to Learn About How Well Riociguat Works, How Safe it is and How it is Used Under Real World Conditions in Patients in the United States Who Are Receiving Riociguat for High Blood Pressure in the Arteries That Carry Blood From the Heart to the Lungs (Pulmonary Arterial Hypertension, PAH)
Started Jul 2021
500 enrolled
Pulmonary Arterial Hypertension
THERAPY-HYBRID-BPA Trial
Started Oct 2020
72 enrolled
Hypertension, Pulmonary
Riociguat rEplacing PDE-5i Therapy evaLuated Against Continued PDE-5i thErapy
Started Jan 2017
225 enrolled
Pulmonary Arterial Hypertension
Loss of Exclusivity
LOE Date
Feb 18, 2034
96 months away
Patent Expiry
Feb 18, 2034